BioGeneration Ventures (BGV), a Naarden, The Netherlands-based early stage life sciences venture capital firm with funds focused on European biotechnology companies, received an additional investment, taking the total capital commitments to €66m, out of a maximum €75m.
Backers included the European Investment Fund, whose contribution comes from InnovFin Equity Facility, and the Dutch Venture Initiative II.
The firm’s third fund will focus on therapeutics, medical devices and diagnostics, within Europe, in particular in Benelux and Germany. Four investments have already been made from the fund into German immuno- oncology company Catalym, and Dutch companies Escalier Biosciences, Scenic Biotech and Varmx, working on autoimmune diseases, target discovery, and haematology respectively.
Led by Edward van Wezel, Managing Partner, BGV operates as a joint venture with Forbion Capital Partners, providing access to the later stage perspective on early innovation and a global network of experts and pharma companies. The BGV team has broad experience in investment, life sciences, business development, and commercial operations.
The team includes experienced biotech entrepreneurs as venture partners and advisors.
Successful investments include divestment of Dezima Pharma to Amgen for up to USD 1.55 billion in total deal value and in Acerta Pharma for up to USD 7 billion with a guaranteed payment of USD 4 billion.
In both companies BGV was founding investor.